TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19398387
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections with varying volumes
Study: 19398387
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections with the same volume
Study: 19398387
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections with different volumes
Study: 17303369
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (C)
Study: 7908865
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous nutrition (0.2 g of N and 103 non-protein kJ/kg body weight)
Study: 7908865
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition enriched with branched-chain amino acids (0.2 g of N with 30% from branched-chain amino acids and 103 non-protein kJ/kg body weight)
Study: 29655984
Drug: Motor affordance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor affordance program at home for infants (G-2)
Study: 29655984
Drug: Motor affordance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor affordance program at home for infants (G-1)
Study: 21986137
Drug: Single-injection local
Normalized name: LOCAL ANESTHETICS,INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection local infiltration analgesia (SLIA)
Study: 15379315
Drug: six flavor
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: six flavor glutinous rehmannis pill
Study: 9020492
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum concentrations of HCG > 1000 IU l(‐1)
Study: 9020492
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum concentrations of AFP > 1000 IU l(‐1)
Study: 7885970
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (100 mg ZDV after an 8-hour fast)
Study: 7885970
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (100 mg ZDV with a high-fat breakfast)
Study: 7885970
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (100 mg ZDV 3 hours after a high-fat breakfast)
Study: 2897986
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of terfenadine and 300 mg of flurbiprofen per day
Study: 31619442
Drug: Berberine 900
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 900 mg/day
Study: 30212239
Drug: Tiotropium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (5 μg/day)
Study: 30212239
Drug: No add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: No add-on therapy
Study: 26071277
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose (300 mg or 900 mg)
Study: 23668548
Drug: Nebulized cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized cyclosporine (300 mg of CIS, 62.5 mg/mL CsA in propylene glycol)
Study: 23668548
Drug: Nebulized cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized cyclosporine (300 mg of CIS)
Study: 17572575
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg intravenously intraoperatively followed by a 6-day oral tapering dose of methyl-prednisone)
Study: 17572575
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received neither agent)
Study: 7740468
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus 100 mg aspirin
Study: 26566149
Drug: Trimethoprim, 200
Normalized name: Trimethoprim, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim, 200 mg twice daily
Study: 6605713
Drug: Cephalexin, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin, 250 mg four times daily
Study: 20506328
Drug: Drug Eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Eluting Stents (DES)
Study: 26559572
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy plus PCI (PCI group)
Study: 26559572
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone (medical‐therapy group)
Study: 26559572
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (PCI and medical therapy)
Study: 24333824
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG); 12×90 minutes weekly sessions: psychoeducational group intervention
Study: 18928089
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine (modified Jiawei Danggui Decection + 10 mg Loratadine tablet, once daily) for 4 weeks
Study: 18928089
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine (10 mg Loratadine tablet, once daily) for 4 weeks
Study: 12580913
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized extract for 4-5 years
Study: 1595847
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with pethidine 25 mg
Study: 1595847
Drug: 0.1875% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1875% bupivacaine with pethidine 25 mg
Study: 1595847
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with pethidine 25 mg
Study: 29728331
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg MDMA plus psychotherapy
Study: 29728331
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg MDMA plus psychotherapy
Study: 29728331
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg MDMA plus psychotherapy
Study: 29728331
Drug: Open-label crossover
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label crossover with full-dose MDMA (100-125 mg) after 30 mg
Study: 29728331
Drug: Open-label crossover
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label crossover with full-dose MDMA (100-125 mg) after 75 mg
Study: 29728331
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups after full-dose MDMA (100-125 mg) at 12-month follow-up
Study: 24969368
Drug: Jia‐Wei‐Xiao‐Yao‐San (JWXYS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jia‐Wei‐Xiao‐Yao‐San (JWXYS) with Cyperus rotundus L.
Study: 24969368
Drug: Cyperus rotundus
Normalized name: CYPERUS ROTUNDUS ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyperus rotundus L. with Leonurus heterophyllus Sweet
Study: 22131999
Drug: Grass Allergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass Allergy Immunotherapy Tablet (AIT) with CED
Study: 22131999
Drug: Grass Allergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass Allergy Immunotherapy Tablet (AIT) without CED
Study: 20855244
Drug: Shengmai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai capsule
Study: 16275616
Drug: Desloratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (5 mg/daily)
Study: 16275616
Drug: Levocetirizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (5 mg/daily)
Study: 12594141
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg ml(‐1) (with glucose 50 mg ml(‐1)), 3 ml
Study: 12594141
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg ml(‐1) (with glucose 80 mg ml(‐1)), 3 ml
Study: 11064438
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of synthetic peptide MBP82-98 (DEN(85)VVHFFKNIVTP(96)RT)
Study: 11064438
Drug: IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline injections every 6 months for the first 2 years
Study: 8759564
Drug: Ranitidine (Zantac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (Zantac effervescent tablets) 150 mg bd for two weeks, increased to qds for non-responders in the last two weeks.
Study: 8759564
Drug: Ranitidine (Zantac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (Zantac effervescent tablets)
Study: 1290245
Drug: Accupro monotherapy
Normalized name: Accupro
DrugBank: Quinapril (DB00881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accupro monotherapy (5 mg to 40 mg daily)
Study: 1290245
Drug: Accupro combined
Normalized name: Accupro
DrugBank: Quinapril (DB00881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accupro combined with Diltiazem or a diuretic
Study: 1290245
Drug: Self-recordings taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-recordings taken twice a day
Study: 6405494
Drug: FreAmine III
Normalized name: Freamine III
DrugBank: Magnesium acetate (DB13996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FreAmine III (isonitrogenous amino acid control solution)
Study: 28345961
Drug: SHUTi (Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHUTi (Internet-based cognitive-behavioral treatment for insomnia)
Study: 23110320
Drug: A(H1N1)pmd09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A(H1N1)pmd09 vaccine co-administered with TIV
Study: 23110320
Drug: A(H1N1)pmd09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A(H1N1)pmd09 vaccine sequentially administered with TIV
Study: 23110320
Drug: AS03-adjuvanted A(H1N1)pmd09
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted A(H1N1)pmd09 vaccine
Study: 23110320
Drug: Non-adjuvanted A(H1N1)pmd09
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted A(H1N1)pmd09 vaccine
Study: 23110320
Drug: Adjuvanted A(H1N1)pmd09
Normalized name: Haemagglutinin-strain A(H1N1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted A(H1N1)pmd09 vaccine
Study: 17077346
Drug: Hyperinsulinemic euglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic euglycemic clamp in insulin-resistant obese women
Study: 15755853
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate (4.3 g or 40 mmol/d)
Study: 15755853
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (800 mg or 20 mmol/d)
Study: 15755853
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (potassium citrate and calcium citrate)
Study: 12062733
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg twice daily (n = 17)
Study: 11247166
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with PUFA omega-3 (Eiconol) 8 g/day
Study: 8751516
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass system (Duraflo II)
Study: 1501618
Drug: Non-surgical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical therapy (no Kasai procedure)
Study: 2859255
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol plus oxatomide
Study: 26780408
Drug: Submaximal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submaximal dose of mepivacaine 108 mg with epinephrine 54 μg (group I)
Study: 26780408
Drug: Submaximal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submaximal dose of mepivacaine 216 mg with epinephrine 108 μg (group II)
Study: 18055678
Drug: 3.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g/kg per day amino acid supplementation
Study: 18055678
Drug: 2.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/kg per day amino acid supplementation
Study: 15632536
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (group F, n = 60)
Study: 15632536
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl combined with bupivacaine infiltration (group FB, n = 60)
Study: 10215955
Drug: Intranasal DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DDAVP (300 microg)
Study: 7486483
Drug: Ribavirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (600 mg twice daily for 12 months)
Study: 2278056
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dose of quinine, quinidine and cinchonine combination
Study: 2278056
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dose of quinine, quinidine and cinchonine combination
Study: 31320735
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant (IVD)
Study: 21449624
Drug: Drug Renal
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug Renal Alert Pharmacy (DRAP) program
Study: 18798228
Drug: Causal beliefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Causal beliefs (psychological, biological addiction, ambiguous)
Study: 16902049
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg/kg (15 mg maximum)
Study: 16136902
Drug: Long-term domiciliary
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term domiciliary oxygen therapy (LTDOT)
Study: 21136031
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment only)
Study: 9597374
Drug: Metformin up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin up to 2000 mg/day
Study: 9597374
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg daily (control)
Study: 7871082
Drug: lorazepam 0.026
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 0.026 mg/kg
Study: 3209284
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 5 micrograms kg‐1 90 min before induction of anesthesia
Study: 29516486
Drug: Prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg + diphenhydramine 25 mg IV
Study: 28409385
Drug: Dietary folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary folic acid 1.0 mg/kg
Study: 28409385
Drug: Dietary folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary folic acid 2.0 mg/kg
Study: 28409385
Drug: Dietary folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary folic acid 5.0 mg/kg
Study: 28409385
Drug: Dietary folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary folic acid (0.0 mg/kg)
Study: 26213796
Drug: Active comparison
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparison treatments
Study: 23579349
Drug: HF toolkit,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF toolkit, 2 onsite meetings, and a monthly phone call
Study: 1642580
Drug: Fixed mini-dose
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed mini-dose warfarin (1 mg daily)
Study: 1642580
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (to maintain INR of 2.0-4.0)
Study: 6402612
Drug: Cefazolin sodium
Normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin sodium (3 doses)
Study: 20639632
Drug: L-carnitine (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1,500 mg daily for 3 months)
Study: 20639632
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, 31 patients)
Study: 18556425
Drug: SGLT‐IVTJ (subthreshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGLT‐IVTJ (subthreshold grid laser treatment combined with intravitreal triamcinolone injection)
Study: 18556425
Drug: SGLT (subthreshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGLT (subthreshold grid laser treatment)
Study: 17851262
Drug: S-1 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 60 mg/body/day (level 1)
Study: 17851262
Drug: S-1 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 80 mg/body/day (recommended dose)
Study: 17851262
Drug: S-1 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 100 mg/body/day (level 3)
Study: 10733159
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of tetragastrin
Study: 29098393
Drug: DEX (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (1 μg/kg loading dose over 10 min, followed by 0.3-0.5 μg/kg/h continuous infusion)
Study: 23946732
Drug: Oral meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meperidine
Study: 17433840
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy with irbesartan (300 mg/day)
Study: 17433840
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continuation of conventional therapy)
Study: 9420364
Drug: Same treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same treatment without the eye movement
Study: 3087076
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (3 X 300 mg per day for 9 days as continuous intravenous infusion)
Study: 24635772
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin and crystalloid solution
Study: 24635772
Drug: Crystalloid solution
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solution alone
Study: 21518135
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of metformin
Study: 21518135
Drug: 1700 mg
Normalized name: inulin 1700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1700 mg of metformin
Study: 17003660
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (sertraline)
Study: 17003660
Drug: Combined cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive-behavioral therapy and antidepressant medication
Study: 10952585
Drug: Quinine (Q(7))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (Q(7)) in combination with clindamycin (Q(7)C(7))
Study: 10952585
Drug: Quinine (Q(7))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (Q(7)) in combination with tetracycline (Q(7)T(7))
Study: 8831988
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) (4 g/m2) alone (group I)
Study: 8831988
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) (4 g/m2) with recombinant human granulocyte‐macrophage colony stimulating factor (rhGM‐CSF) (5 micrograms/kg/day) (group II)
Study: 8831988
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) (4 g/m2) with rhGM‐CSF (group II)
Study: 24291168
Drug: LT patch
Normalized name: Trans-Ver-Sal 15% Wart Remover Adult Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT patch (37.5 μg of ETEC LT)
Study: 24291168
Drug: LT patch
Normalized name: Trans-Ver-Sal 15% Wart Remover Adult Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT patch
Study: 20865842
Drug: 3.75% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75% imiquimod cream
Study: 18562771
Drug: High-protein, low-calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein, low-calorie diet with 3-g/day fish-oil supplementation
Study: 11126693
Drug: Novel anticancer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel anticancer agents targeting signal transduction and antiangiogenesis
Study: 11126693
Drug: Classical cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical cytotoxic agents
Study: 6437295
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol 10 minutes prior to exercise, in addition to theophylline (serum level 10-20 micrograms/ml)
Study: 6437295
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metaproterenol and cromolyn with theophylline